DLH to Continue Providing R&D and Advanced Technology Services to the Telemedicine and Advanced Technology Research Center
DLH Holdings Corp. (NASDAQ: DLHC) has secured a five-year task order worth up to $37.7 million to continue providing advanced technology services to the Telemedicine and Advanced Technology Research Center (TATRC). The contract, awarded under the OMNIBUS IV procurement vehicle, involves delivering scientific R&D, modeling & simulation, AI, machine learning, robotic process automation, biomedical engineering, and cloud-enabled big data analytics.
The company will support TATRC and the US Army Medical Research & Development Command (MRDC) in their mission to improve medical outcomes for military service members through the fusion of data, humans, and machines. This continuation builds on DLH's 20-year partnership with the medical research & development community, leveraging their comprehensive suite of technology-enabled research and advanced engineering solutions.
DLH Holdings Corp. (NASDAQ: DLHC) ha ottenuto un ordine di lavoro quinquennale del valore fino a 37,7 milioni di dollari per continuare a fornire servizi tecnologici avanzati al Telemedicine and Advanced Technology Research Center (TATRC). Il contratto, assegnato tramite il veicolo di approvvigionamento OMNIBUS IV, prevede la fornitura di ricerca scientifica e sviluppo, modellazione e simulazione, intelligenza artificiale, apprendimento automatico, automazione robotica dei processi, ingegneria biomedica e analisi di big data basate su cloud.
L'azienda supporterà il TATRC e l'US Army Medical Research & Development Command (MRDC) nella loro missione di migliorare i risultati medici per i membri delle forze armate attraverso l'integrazione di dati, persone e macchine. Questa prosecuzione si basa sulla partnership ventennale di DLH con la comunità di ricerca e sviluppo medico, sfruttando il loro ampio ventaglio di soluzioni tecnologiche e ingegneristiche avanzate.
DLH Holdings Corp. (NASDAQ: DLHC) ha asegurado un pedido de trabajo a cinco años por un valor de hasta 37,7 millones de dólares para continuar brindando servicios tecnológicos avanzados al Telemedicine and Advanced Technology Research Center (TATRC). El contrato, adjudicado bajo el vehículo de adquisición OMNIBUS IV, implica la entrega de investigación científica y desarrollo, modelado y simulación, inteligencia artificial, aprendizaje automático, automatización robótica de procesos, ingeniería biomédica y análisis de big data habilitados por la nube.
La compañía apoyará al TATRC y al US Army Medical Research & Development Command (MRDC) en su misión de mejorar los resultados médicos para los miembros del servicio militar mediante la fusión de datos, humanos y máquinas. Esta continuación se basa en la asociación de 20 años de DLH con la comunidad de investigación y desarrollo médico, aprovechando su completo conjunto de soluciones tecnológicas y de ingeniería avanzada.
DLH Holdings Corp. (NASDAQ: DLHC)는 원격의료 및 첨단기술 연구센터(TATRC)에 첨단 기술 서비스를 계속 제공하기 위해 최대 3,770만 달러 규모의 5년 과업 계약을 확보했습니다. OMNIBUS IV 조달 수단을 통해 체결된 이 계약은 과학 연구개발, 모델링 및 시뮬레이션, 인공지능, 머신러닝, 로봇 프로세스 자동화, 생물의학 공학, 클라우드 기반 빅데이터 분석을 포함합니다.
회사는 TATRC 및 미 육군 의학 연구개발 사령부(MRDC)를 지원하여 데이터, 인간, 기계의 융합을 통해 군 복무자의 의료 성과를 향상시키는 임무를 수행합니다. 이번 계약 연장은 DLH가 의료 연구개발 커뮤니티와 20년간 구축해온 파트너십을 기반으로 하며, 첨단 기술 연구 및 고급 엔지니어링 솔루션을 활용합니다.
DLH Holdings Corp. (NASDAQ: DLHC) a obtenu un ordre de mission de cinq ans d'une valeur pouvant atteindre 37,7 millions de dollars pour continuer à fournir des services technologiques avancés au Telemedicine and Advanced Technology Research Center (TATRC). Le contrat, attribué dans le cadre du véhicule d'approvisionnement OMNIBUS IV, implique la fourniture de recherche scientifique et développement, modélisation et simulation, intelligence artificielle, apprentissage automatique, automatisation robotique des processus, ingénierie biomédicale et analyses de big data basées sur le cloud.
L'entreprise soutiendra le TATRC et l'US Army Medical Research & Development Command (MRDC) dans leur mission d'améliorer les résultats médicaux pour les militaires en fusionnant données, humains et machines. Cette continuation s'appuie sur le partenariat de 20 ans de DLH avec la communauté de recherche et développement médical, tirant parti de leur gamme complète de solutions technologiques et d'ingénierie avancée.
DLH Holdings Corp. (NASDAQ: DLHC) hat einen fünfjährigen Aufgabenauftrag im Wert von bis zu 37,7 Millionen US-Dollar erhalten, um weiterhin fortschrittliche Technologiedienstleistungen für das Telemedicine and Advanced Technology Research Center (TATRC) bereitzustellen. Der Vertrag, der über das Beschaffungsinstrument OMNIBUS IV vergeben wurde, umfasst wissenschaftliche Forschung und Entwicklung, Modellierung und Simulation, Künstliche Intelligenz, maschinelles Lernen, robotergestützte Prozessautomatisierung, biomedizinische Technik und cloudbasierte Big-Data-Analysen.
Das Unternehmen wird TATRC und das US Army Medical Research & Development Command (MRDC) bei ihrer Mission unterstützen, medizinische Ergebnisse für Militärangehörige durch die Verschmelzung von Daten, Menschen und Maschinen zu verbessern. Diese Fortsetzung baut auf der 20-jährigen Partnerschaft von DLH mit der medizinischen Forschungs- und Entwicklungsgemeinschaft auf und nutzt deren umfassendes Angebot an technologiegestützten Forschungs- und fortschrittlichen Ingenieurlösungen.
- None.
- None.
Insights
DLH secures $37.7M five-year military contract, continuing 20-year partnership in advanced medical technology development.
This
This contract's importance extends beyond the dollar value - it demonstrates client retention in a highly competitive federal contracting environment. The press release notes DLH's 20-year partnership with the medical research community, indicating exceptional performance and relationship development with this military client.
The award through the OMNIBUS IV procurement vehicle is notable, as these contract vehicles streamline acquisition processes but require vendors to meet stringent qualifications. DLH's continued access to this vehicle suggests strong past performance ratings and compliance with federal contracting requirements.
The task order's focus on advanced technologies - including AI/ML, robotic process automation, biomedical engineering, and cloud analytics - positions DLH at the intersection of defense health and emerging technologies. These specialized capabilities require significant expertise that isn't easily replicated, potentially creating barriers to competition.
For context, TATRC serves as the Army's hub for developing next-generation medical capabilities, focusing on integrating data, human factors, and technology to improve military medical outcomes. This puts DLH in a strategic position to support the Defense Department's ongoing prioritization of military medical readiness and technological advancement.
Operating at the nexus of science and technology, DLH continues to deliver advanced solutions to the medical community
ATLANTA, May 08, 2025 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of science research and development, systems engineering and integration, and digital transformation and cyber security, today announced that it has been awarded a five year task order valued at up to
“For twenty years, DLH has partnered with the medical research & development community to address readiness challenges at the nexus of technology and scientific research,” said Zach Parker, DLH President and CEO. “The strength of this long-standing partnership underscores the ability of our industry-leading engineers, researchers, and technologists to provide impactful, mission-critical solutions. DLH incorporates our technical solutions to efficiently meet the evolving needs of warfighters, ensuring operational readiness from modeling and simulation to the battlefield.”
This
“TATRC and MRDC recognize DLH as an industry leader in information systems, scientific research & development, artificial intelligence, machine learning and robotic process automation plus clinical networks and research. We are transforming medical and scientific research, merging it with technology to optimize military health systems,” stated Dr. Vicki Hart, DLH Strategic Account Executive for Science, Research & Development markets.
“We are confident that the cutting-edge capabilities we deploy on behalf of the military’s vital missions position us well for similarly aligned pursuits across the military health and adjacent markets,” Parker continued.
About DLH
DLH (NASDAQ: DLHC), a Russell 2000 company, enhances technology, public health, and cyber security readiness missions through science, technology, cyber, and engineering solutions and services. Our experts solve some of the most complex and critical missions faced by customers today, leveraging digital transformation, artificial intelligence, advanced analytics, cloud-based applications, telehealth systems, and more. With over 2,400 employees dedicated to the idea that “Your Mission is Our Passion,” DLH brings a unique combination of technology, innovation, and world-class expertise, to improve lives across the globe. For more information, visit www.DLHcorp.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or DLH`s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that the Company or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or DLH’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements in this release include, among others, statements regarding estimates of future revenues, operating income, earnings and cash flow. These statements reflect our belief and assumptions as to future events that may not prove to be accurate. Our actual results may differ materially from such forward-looking statements made in this release due to a variety of factors, including: the risk that we will not realize the anticipated benefits of acquisitions (including anticipated future financial performance and results); the diversion of management’s attention from normal daily operations of the business and the challenges of managing larger and more widespread operations; the inability to retain employees and customers; contract awards in connection with re-competes for present business and/or competition for new business; our ability to manage our debt obligations; compliance with bank financial and other covenants; changes in client budgetary priorities; government contract procurement (such as bid and award protests, small business set asides, loss of work due to organizational conflicts of interest, etc.) and termination risks; the impact of inflation and higher interest rates; and other risks described in our SEC filings. For a discussion of such risks and uncertainties which could cause actual results to differ from those contained in the forward-looking statements, see “Risk Factors” in the Company’s periodic reports filed with the SEC, including our Annual Report on Form 10-K for the fiscal year ended September 30, 2024 as well as subsequent reports filed thereafter. The forward-looking statements contained herein are not historical facts, but rather are based on current expectations, estimates, assumptions and projections about our industry and business.
Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company does not assume any responsibility for updating forward-looking statements, except as may be required by law.
CONTACTS:
INVESTOR RELATIONS
Contact: Chris Witty
Phone: 646-438-9385
Email: cwitty@darrowir.com
FAQ
What is the value and duration of DLH Holdings' (DLHC) new TATRC contract?
What services will DLH Holdings (DLHC) provide to TATRC under the new contract?
How long has DLH Holdings (DLHC) been partnering with the medical research community?
Who is TATRC and what is their mission?
